Linical Co. Ltd. | Cash Flow

Fiscal year is April-March. All values JPY Millions.
2014
2015
2016
2017
2018
2019
Net Income before Extraordinaries
704
735
1,986
2,011
1,826
1,164
Depreciation, Depletion & Amortization
16
88
191
203
210
451
Other Funds
411
250
383
749
601
662
Funds from Operations
309
573
1,794
1,464
1,436
953
Changes in Working Capital
60
117
23
827
76
1,745
Net Operating Cash Flow
249
690
1,817
2,292
1,360
792
Capital Expenditures
15
54
51
69
99
Sale of Fixed Assets & Businesses
-
-
137
-
-
Purchase/Sale of Investments
-
114
23
306
120
Net Investing Cash Flow
115
1,365
48
375
92
Cash Dividends Paid - Total
188
159
159
228
227
Issuance/Reduction of Debt, Net
75
982
535
168
192
Net Financing Cash Flow
263
822
694
457
472
Net Change in Cash
125
148
1,155
1,444
818
Free Cash Flow
238
676
1,779
2,263
1,299
Net Assets from Acquisitions
94
1,197
-
-
-
Other Sources
1
-
-
-
159
Change in Capital Stock
-
-
-
61
52
Exchange Rate Effect
-
4
16
16
22
Other Uses
6
1
16
-
32

About Linical Co.

View Profile
Address
Shin-Osaka Brick Building, 10/F
Osaka Osaka 532
Japan
Employees -
Website http://www.linical.co.jp
Updated 07/08/2019
Linical Co., Ltd. engages in pharmaceutical contract research projects providing consulting, monitoring, and quality control services to pharmaceutical companies. It operates through the Contract Research Organization (CRO) Business and Contract Sales Organization (CSO) Business segments. The CRO Business segment provides outsourced pharmaceutical development services.